Subgroups & Missing Data: The Problems Facing HTAs In Europe
ATMPs A Particular Challenge
The DIA Europe 2020 conference heard from regulators and health technology assessment bodies about the problems that can arise over poorly defined patient populations and a lack of comparator data when making reimbursement decisions.
You may also be interested in...
The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.
Panelists at the virtual DIA Europe 2020 conference heard some good news about progress with the EU’s parallel consultation system for scientific advice, and some not so good news about continuing differences in health technology assessments at national level across Europe.
Pharmaceutical companies should be obliged to carry out comparative trials, according to analysis from Germany’s Institute For Quality and Efficiency in Healthcare, IQWiG.